Journalists Discuss Insulin Costs and Ethical Questions Surrounding a North Carolina Rehab Program
KHN staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Drugs
401 - 420 of 1,303 Results
-
-
California Handed Its Medicaid Drug Program to One Company. Then Came a Corporate Takeover.
The company awarded the state’s Medi-Cal Rx contract was taken over by another company, Centene. That left the state with a contractor it didn’t pick — one that has been accused of overbilling nine other state Medicaid programs and is now under investigation by California.
-
KHN’s ‘What the Health?’: Finally, a Fix for the ‘Family Glitch’
President Joe Biden welcomed former President Barack Obama back to the White House this week to announce a new policy for the Affordable Care Act that would make subsidies available to more families with unaffordable employer coverage. Meanwhile, Congress struggled to find a compromise for continued federal funding of covid-19 vaccines, testing, and treatments. Tami Luhby of CNN, Shefali Luthra of The 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
-
Despite Doctors’ Concerns, Pharmacists Get More Leeway to Offer Treatment With Testing
In the battle against covid, pharmacies became a key place for consumers to seek vaccines and testing. Some states are expanding pharmacists’ work to include directly prescribing drugs for customers who seek some routine, point-of-care tests, such as those for flu or strep throat. But doctor groups oppose the move.
-
At a Tennessee Crossroads, Two Pharmacies, a Monkey, and Millions of Pills
Prosecutors say opioid-seeking patients drove hours to get their prescriptions filled in Celina, Tennessee, where pharmacies ignored signs of substance misuse and paid cash — or “monkey bucks” — to keep customers coming back.
By Brett Kelman -
Big Pharma Is Betting on Bigger Political Ambitions From Sen. Tim Scott
The South Carolina senator led the congressional pack in pharma campaign contributions for the second half of 2021. There are clear reasons.
By Rachana Pradhan and Victoria Knight -
Campaign Contributions Tracker
Pharma Cash to Congress
A KFF Health News database tracks campaign donations from drugmakers over the past 10 years.
-
Pfizer CEO Pushes Yearly Shots for Covid. Not So Fast, Experts Say.
A corporate CEO’s call for a fourth mRNA shot struck those closely watching the pandemic as self-serving. It creates public pressure for a fourth dose of vaccine before government experts have time to assess the evidence and settle on the best course forward.
By Arthur Allen -
Covid’s ‘Silver Lining’: Research Breakthroughs for Chronic Disease, Cancer, and the Common Flu
Billions of dollars invested in mRNA vaccines and covid research could yield health care dividends for decades to come.
By Liz Szabo -
‘An Arm and a Leg’: Need an Expensive Drug? Here’s What You Need to Know
Even a personal finance expert can get stuck with a huge unexpected bill for a drug. Listen up for what you need to know about "copay accumulators."
-
Which Companies Aren’t Exiting Russia? Big Pharma
U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.
By Sarah Varney -
Patients Divided Over Alzheimer’s Drug: Is It a ‘Risk I’m Willing to Take’ or Just a ‘Magic Pill’?
Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.
-
$35 Insulin Cap Is Welcome, Popular, and Bipartisan. But Congress May Not Pass It Anyway.
Spun off from the ailing but not-quite-dead Build Back Better legislation, a popular proposal to cap out-of-pocket insulin costs at $35 a month faces tough political realities that could kill it.
-
California Governor’s Big Promises on Drug Prices Are Slow to Materialize
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings haven’t been as monumental as he promised. And his plan to have California make its own generic drugs hasn’t gotten off the ground.
-
HIV Preventive Care Is Supposed to Be Free in the US. So, Why Are Some Patients Still Paying?
The Department of Labor issued rules in July clarifying that health plans need to cover the costs of prescription drugs proven to prevent HIV infection, along with related lab tests and medical appointments, at no cost to patients. More than half a year later, the erroneous billing continues.
By Sarah Varney -
Fact Check: Biden Sets High Bar in 1st State of the Union Speech
What a difference a year makes. The speech was delivered to a largely unmasked crowd of lawmakers, justices, and Cabinet members in the House chamber.
By Victoria Knight and Colleen DeGuzman -
Changes to Medi-Cal’s Troubled Drug Program Reduce Backlog in California, but Problems Persist
After a troubled start to the new Medi-Cal prescription drug program, the state’s contractor has hired staffers to reduce wait times for medication approvals and patients seeking help. But some doctors and clinics report that patients continue to face delays.
-
Journalists Review Hospital Penalties and Problems Riddling Medicaid Rx Program
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
KHN’s ‘What the Health?’: It’s Health Costs, Stupid (2022 Edition)
As the pandemic wanes, for now, the ever-rising cost of health care is again taking center stage. Meanwhile, a year into the Biden administration, the FDA finally has a Senate-confirmed commissioner, Dr. Robert Califf. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Hannah Wesolowski of the National Alliance on Mental Illness, about how the pandemic has worsened the nation’s mental health crisis and what can be done about it.
-
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
By Arthur Allen